On November 4, 2025, Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures, and select individual investors. Wilson Sonsini Goodrich & Rosati advised Azalea Therapeutics on the transaction.

The company’s mission is to engineer therapeutic cells with precision directly inside the patient, transforming how cell and gene therapies are created and delivered. Azalea Therapeutics’ EDV technology selectively targets cells, delivering transient CRISPR-Cas9 cargo to mediate programmable genome editing. Funds from the financing round will be used to advance Azalea Therapeutics’ CD19-based in vivo CAR-T therapy for B cell malignancies and autoimmune diseases through IND-enabling studies and into the clinic, progress its BCMA-targeted in vivo CAR-T program for multiple myeloma and an undisclosed program for solid tumors, while exploring expansion of the platform to other cell types.

The Wilson Sonsini team that advised Azalea Therapeutics on the transaction includes:

Corporate
Ken Clark
David Pirko
Helen Qi
Victoria Burch
Aaron Gordon

Technology Transactions
David Pirko
Rachel Slyker

Tax
Myra Sutanto Shen
Anjali Krishnan

Regulatory
Anne Seymour
Seth Cowell

For more information, please see Azalea's news release. Additional coverage can be found on Fierce Biotech.